Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a

Neurology

Volumn 72, Issue 23, 2009, Pages 1989-1993

  Rudick, R A ^a   Pace, A ^b   Rani, M R S ^a   Hyde, R ^b   Panzara, M ^b   Appachi, S ^a   Shrock, J ^a   Maurer, S L ^c   Calabresi, P A ^d   Confavreux, C ^e   Galetta, S L ^f   Lublin, F D ^g   Radue, E W ^h   Ransohoff, R M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BIOGEN   (United States)

^c Scientific Connexions   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e HÔPITAL NEUROLOGIQUE   (France)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA1A INTERFERON; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NATALIZUMAB; PRAVASTATIN; SIMVASTATIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE COURSE; FATIGUE; GENE INDUCTION; HUMAN; HYPERLIPIDEMIA; LIMB PAIN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MYALGIA; POST HOC ANALYSIS; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; SIDE EFFECT;

EID: 67649488058     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a92b96     Document Type: Article

References (10)

1. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46:1855-1862.
2. Wekerle H. Tackling multiple sclerosis. Nature 2002;420: 39-40.
3. Youssef S, Stüve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
4. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923.
5. Schlaak JF, Hilkens CM, Costa-Pereira AP, et al. Cell-type and donor-specific transcriptional responses to interferonalpha. Use of customized gene arrays J Biol Chem 2002; 277:49428-49437.
6. Lindbom J, Ljungman AG, Lindahl M, Tagesson C. Increased gene expression of novel cytosolic and secretory phospholipase A (2) types in human airway epithelial cells induced by tumor necrosis factor-alpha and IFN-gamma. J Interferon Cytokine Res 2002;22:947-955.
7. Rani MRS, Foster GR, Leung S, et al. Characterization of --R1, a gene that is selectively induced by interferon-- (IFN--) compared with IFN--. J Biol Chem 1996;271: 22878-22884.
8. Rani MRS, Pandalai S, Shrock J, et al. Requirement of catalytically active TYK2 and accessory signals for the induction of TRAIL mRNA by IFN--. J Interferon Cytokine Res 2007;27:767-779.
9. del Pozo MA, Price LS, Alderson NB, et al. Adhesion to the extracellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. EMBO J 2000; 19:2008-2014.
10. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008;71: 1390-1395.